Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 10/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.49 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5096987 | 0.85 | HPGD (0.55) | HPGDHTTTSHRALDH1A1KMT2A | |
| SCHEMBL5070484 | 0.84 | HPGD (0.54) | HPGDHTTTSHRALDH1A1KMT2A | |
| SCHEMBL542082 | 0.83 | HPGD (0.54) | HPGDHTTTSHRALDH1A1KMT2A | |
| SCHEMBL11454853 | 0.83 | HPGD (0.54) | HPGDHTTTSHRALDH1A1KMT2A | |
| SCHEMBL4160200 | 0.81 | HPGD (0.58) | HPGDHTTTSHRALDH1A1KMT2A | |
| Terephthalamide SCHEMBL1181439 | 0.81 | HPGD (0.52) | HPGDHTTTSHRALDH1A1KMT2A | |
| SCHEMBL24016888 | 0.81 | HPGD (0.55) | HPGDHTTTSHRALDH1A1KMT2A | |
| SCHEMBL1538037 | 0.80 | HPGD (0.51) | HPGDHTTTSHRALDH1A1KMT2A | |
| SCHEMBL24016907 | 0.80 | KMT2A (0.60) | HPGDHTTTSHRALDH1A1KMT2A | |
| SCHEMBL1159852 | 0.79 | HPGD (0.57) | HPGDHTTTSHRALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1390357-A2 | ANTI-THROMBOTIC COMPOUNDS, PRODUCTION AND USE THEREOF AS MEDICAMENTS | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2004-02-25 | — | — | EP | disclosed |
| US-20020151534-A1 | Antithrombotic compounds | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-10-17 | — | — | US | disclosed |
| WO-2002062778-A2 | ANTI-THROMBOTIC COMPOUNDS, PRODUCTION AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020151534-A1 | Antithrombotic compounds | SERPINC1, PF4, F2 | HPGD 569/4885HTT 452/4885TSHR 4008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.